Diabetes | CHOP Research Institute


The goal of this Phase 2 study is to assess safety and efficacy of frexalimab to preserve β-cell function in participants with newly diagnosed type 1 diabetes (T1D).

Promoting and fostering new research ventures and collaborations among our community of basic and translational investigators, clinician-scientists, and clinicians with shared interests in skeletal health and diseases

The purpose of this study is to evaluate the safety and pharmacokinetics (drug levels in the blood) of teplizumab in children less than 8 years old.

The goal of this study is to identify a safe dosing regimen for siplizumab in participants with type 1 diabetes.

Published on
Jul 29, 2022
Dr. Levine’s great pastimes outside of his endocrinology lab are crossword puzzles and flying radio-controlled airplanes with his grandsons.
Published on
Apr 28, 2022
Our Featured Trainee for April, Anna Ada Dattoli, PhD, discusses Celebrate Diversity Month and her research on diabetes.

Dr. Hatch-Stein's research interests include diabetes, thyroid disorders, and disorders of growth and puberty. Recent clinical research projects include "Bone Health and Cardiovascular Risk in Turner Syndrome" and "Patterns of Height Velocity in Down Syndrome."

hatchsteinj [at] chop.edu

This is a study that investigates whether an IV medication (teplizumab) will slow or halt the progression of type 1 diabetes in children and adolescents (ages 8 - 17 years).

We are currently enrolling adolescents ages 15-21 of South Asian ancestry, African American ancestry, and European American or "White" ancestry.

You are invited to take part in a voluntary research trial because you have type 2 diabetes and are between the ages of 10 and 17 years.